Login to Your Account



NewCo News: Ariel Aims to Reduce the Risk in CNS Development

By Trista Morrison


Monday, October 3, 2011
If the success rate for drug development overall is bad, the success rate for central nervous system (CNS) drug development can only be described as abysmal, thanks to high placebo effects, low patient compliance, subjective endpoints and the difficulties of the blood-brain barrier.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription